Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f0d2:0:b0:441:282b:bd with SMTP id x18csp753686wro; Tue, 28 Apr 2026 16:52:42 -0700 (PDT) X-Received: by 2002:a05:622a:586:b0:50d:7f4d:93cf with SMTP id d75a77b69052e-5100e0fc0bemr72538631cf.8.1777420361800; Tue, 28 Apr 2026 16:52:41 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777420361; cv=none; d=google.com; s=arc-20240605; b=kB/W5LbwFyPtLlg+Bpg2xt860/Iu6Etn4bu7PLphOzRvTRRm2/PPoWOFoWHIoYVrG1 pdDLj7eKbl5JmW+WBbYn4lteNEaf/6kfxlcQnGq7GzGxCUQKO7nSKKzMKZGFHTVtn8t3 f4NU3sU8Se1bVRWeE3/DXpAjpRgKjd2A4inEeQdjKtWdLTKAZCJYlZoLZQ25ELeBShkv bP6mKhQZlqbo0969tTWAN7AXVOrmltV00+RaQozCtQTwIUqpma/H5Yf6SqxJnOk/EaA8 M0+TX2DKSry0j5HEqkbTiYeS8ds0q5eHJ+yHJBwx0JxCtOAbX2scKn0WF/HMs29z5IXH uvqA== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=QMAwxaW6Vox14LRCNC7tKYXCsmzypLGefxzxyheJDys=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=ilWWNIx1q0O1KrMEVI4ai4w/U9vVvhOaEkO5JZ2IAZBR4Ks3B+t9crlxT3ylLpXNAO qfQAIfuG6fP7C0zooC1FjAsfxpzV+BGff2G56PPI6Vtomr5AMlVrf/ceBCV4s9jbZy8P vkYMSp2bpMtpDPfjohtMtJk4sAZKjjSaXk33LP8sn5LkZi7hnstX0sgY9Uv+aPqU8IIO t9xlwIjP4nBhSeHxjlBkxyALNEBrSjo/LwNtvEUv4BgDxg459gNq9Wg4ypIi3upg2fWF 8/bKB1OnH2wSKcIvo0GKuNt/J9EFUAudsYYFhSKHpImILqGHxO36j5/7bQNl1RyVcTao PyDw==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=Qr67QzeV; dkim=pass header.i=@mailgun.org header.s=mg header.b=Syi7atT7; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.45 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v545.v5375b7fa.use4.send.mailgun.net (v545.v5375b7fa.use4.send.mailgun.net. [159.112.244.45]) by mx.google.com with UTF8SMTPS id d75a77b69052e-5101ae7d329si5461991cf.180.2026.04.28.16.52.41 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Tue, 28 Apr 2026 16:52:41 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.45 as permitted sender) client-ip=159.112.244.45; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=Qr67QzeV; dkim=pass header.i=@mailgun.org header.s=mg header.b=Syi7atT7; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.45 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1777420361; x=1777427561; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=QMAwxaW6Vox14LRCNC7tKYXCsmzypLGefxzxyheJDys=; b=Qr67QzeVToXh3OBc9k2L1o9VAr3KllvZAZ2hJp0eGb1oHViyL+p61Hz92NUEsvohObmoC+M08qG85OaIqUcxijM10eDFhOrrJTlg3hJn9bUENk3Jc4IK6ZMlFmWnJUsprO//d9ILcQUCeAdotBaQYTsxYFF385hTaK5XgjvdzbM= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1777420361; x=1777427561; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=QMAwxaW6Vox14LRCNC7tKYXCsmzypLGefxzxyheJDys=; b=Syi7atT72jWkusyBlXYA7w0rNwIHh7ODnEAaNx/atgYTKfY8c9TfXKMMM6UGUKeIALLFevj+Uj3Uyaj72iOia+G+jnJCMNXwJ5CrXMmLxvfIC//lm/gUsOOa+IgrN+WbAelafdD9fO+p1tsR97Fx1dN15udea/FcvpqrMzNa7CA= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by 893a963cb5ef0582f3dfcc4b28c13bb8e109fbb459676368a683208dff30f922 with HTTP id 69f1484833ab1b64f0d587be; Tue, 28 Apr 2026 23:52:40 GMT X-Mailgun-Sending-Ip: 159.112.244.45 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="f293934ab6237258b5faca002d67a2252defc5c892e0a591f07df086a11b" Subject: Mold Toxicity & Peptides: A Comprehensive Walkthrough From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260428235208.3.267a6a86725d2ec6@mg-d0.substack.com> Date: Tue, 28 Apr 2026 23:52:08 +0000 Feedback-Id: post-195815180:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1777420360462", "is_freemail": "true", "post_audience": "everyone", "post_id": "195815180", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --f293934ab6237258b5faca002d67a2252defc5c892e0a591f07df086a11b Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/mold-toxici= ty-and-peptides-a-comprehensive Read this first: Everything below is for research and educational purposes = only. Nothing here is medical advice. All peptide references are framed for= research subjects (RS), not for human consumption. If you think you=E2=80= =99re dealing with mold illness, work with a qualified clinician who knows = this terrain. Section 1: What Mold Toxicity Actually Is You=E2=80=99ll hear this called several names =E2=80=94 mold illness, bioto= xin illness, or its clinical name CIRS (Chronic Inflammatory Response Syndr= ome). They all describe the same thing: a multi-system illness that develop= s when someone with a susceptible immune system gets exposed to water-damag= ed buildings and the toxins they harbor. Those toxins include: Mycotoxins =E2=80=94 poisonous compounds produced by mold itself Endotoxins =E2=80=94 fragments of bacterial cell walls (water damage breeds= bacteria too, not just mold) Beta-glucans =E2=80=94 pieces of fungal cell walls that trigger immune resp= onses Inflammagens =E2=80=94 a catch-all term for anything in the environment tha= t drives inflammation Here=E2=80=99s the part most people miss: healthy immune systems generally = clear all of this. The people who end up stuck in CIRS almost always had so= mething else going on first =E2=80=94 chronic infections (Lyme, Epstein-Bar= r, co-infections), a heavy metal burden, prior viral hits, or significant u= nrelenting stress. Mold is usually the straw that breaks the camel=E2=80=99= s back, not the only problem in the barn. This is why one family member can be completely wrecked while everyone else= in the same house feels fine. Same exposure, different immune terrain. Section 2: How Mold Wrecks The Immune System This section gets a bit technical, but it matters because the peptide proto= col makes a lot more sense once you understand what=E2=80=99s actually brok= en. The TH1/TH2 imbalance. Your immune system has two main =E2=80=9Carms=E2=80= =9D: TH1 is your killer side =E2=80=94 natural killer cells, cytotoxic T-cells, = the parts that hunt down and destroy infections, abnormal cells, and cancer= s TH2 is your antibody/inflammatory side =E2=80=94 useful in normal amounts, = but when it dominates you get allergies, autoimmunity, and mast cell proble= ms In CIRS, TH1 gets suppressed and TH2 goes up. So your ability to fight infe= ctions drops while your ability to inflame and react to everything goes thr= ough the roof. Worst of both worlds. T-cell exhaustion. Imagine an employee who=E2=80=99s been overworked for ye= ars. They still show up, but they=E2=80=99ve checked out. That=E2=80=99s wh= at happens to immune cells under chronic insult. They=E2=80=99re physically= present in lab tests but functionally useless. Same thing happens in cance= r. Mitochondrial dysfunction. Mitochondria are the energy producers inside you= r cells. When they break down, the cell can=E2=80=99t generate enough ATP (= cellular energy) to do basic things =E2=80=94 including pushing toxins out.= This is why people on binders for years still don=E2=80=99t detox. The gar= bage trucks are running, but the houses can=E2=80=99t carry the trash to th= e curb. Immune activation of coagulation. When the body senses chronic infection or= inflammation, it lays down fibrin (a sticky protein web) trying to wall of= f invaders. The problem: that fibrin coats your cells and slows everything = down. Oxygen that normally takes about 2 seconds to enter a cell can take u= p to 2 minutes. That=E2=80=99s where the =E2=80=9Cair hunger=E2=80=9D feeli= ng comes from =E2=80=94 your lungs are fine, but your cells are starving. Pineal/HPA axis dysfunction. The pineal gland and hypothalamus-pituitary ax= is run the body=E2=80=99s master hormonal commands. When they get dysregula= ted, you see the classic CIRS pattern =E2=80=94 suppressed TSH, low T3, =E2= =80=9Ctired but wired,=E2=80=9D disrupted sleep, and standard thyroid panel= s that look =E2=80=9Cnormal=E2=80=9D while the person feels like they=E2=80= =99re dying. Barrier collapse. The gut lining and the blood-brain barrier are supposed t= o be selective walls. In CIRS they get leaky, which is part of why MCAS (ma= st cell activation syndrome =E2=80=94 basically an immune system that react= s to everything) so often shows up alongside mold illness. The biomarkers clinicians track for this: C4a, TGF-=CE=B21, MSH, VIP, MMP-9= , and natural killer cell activity. A note on testing =E2=80=94 Quest tends= to mishandle the NK activity test. LabCorp is more reliable for that one s= pecifically. Section 3: The Two Approaches =E2=80=94 Downstream vs. Upstream The classical approach to mold treatment uses binders (compounds like chole= styramine that grab toxins in the gut and carry them out). This works, but = it=E2=80=99s downstream =E2=80=94 you=E2=80=99re catching toxins after they= =E2=80=99re already loose, hoping to clear them faster than they=E2=80=99re= being released. It can take 5 to 8 years on this approach, and a lot of pe= ople stall out. The newer framework looks upstream =E2=80=94 fix the immune system and mito= chondria first, then detox. The logic: If your immune system is broken, it can=E2=80=99t recognize or clear what= =E2=80=99s colonizing you If your mitochondria can=E2=80=99t make energy, your cells physically can= =E2=80=99t push toxins out If your barriers are leaky, you=E2=80=99re re-absorbing what you just excre= ted Fix the upstream problems and the downstream cleanup goes from years to mon= ths. Binders still have a role =E2=80=94 they just work way better when the= system is primed to actually use them. Section 4: Why Peptides Fit Here Peptides are short chains of amino acids (the building blocks of proteins).= They=E2=80=99re naturally occurring signaling molecules =E2=80=94 your bod= y makes thousands of them. They tell cells what to do. There are two main categories worth knowing for this conversation: Peptides (general category) =E2=80=94 usually 5 to 50 amino acids long. The= y sit on cell surface receptors and trigger a cascade of effects inside the= cell. Think of them as keys that fit specific locks. Bioregulators =E2=80=94 a smaller subcategory, only 2 to 4 amino acids long= =2E Because they=E2=80=99re so small, they= slip into the cell, into the nucle= us, and bind directly to genes. They work epigenetically, meaning they infl= uence which genes get turned on or off without changing the DNA itself. Bio= regulators are gentle, slow-onset, and rarely cause reactions =E2=80=94 whi= ch makes them ideal for sensitive research subjects. The reason peptides work so well together: unlike pharmaceuticals, where st= acking drugs multiplies side effects, peptides tend to complement each othe= r. You can layer a bioregulator with two or three peptides and get a synerg= istic effect rather than a toxicity problem. A note on oral peptides: when a peptide is capped (chemists add an acetyl g= roup to one end and an amide group to the other), it survives stomach acid = and absorbs well. Uncapped peptides get destroyed before they can work. The= =E2=80=9Carginine salt=E2=80=9D version of certain peptides looks similar = on a label but doesn=E2=80=99t survive =E2=80=94 it=E2=80=99s marketed as = =E2=80=9Cstable=E2=80=9D but functionally less effective. Section 5: The Layered Research Framework This is the sequencing that=E2=80=99s emerging from clinical observation. E= ach layer prepares the system for the next. Skipping ahead causes problems = =E2=80=94 running offensive peptides before defensive ones is a common mist= ake that produces severe reactions. Layer 1 =E2=80=94 Calm and Modulate For sensitive research subjects (which most CIRS-affected RS are), bioregul= ators come first. They=E2=80=99re the gentlest entry point and rarely produ= ce reactions. Thymus bioregulator =E2=80=94 modulates the immune system as a whole, the f= oundation peptide Pineal bioregulator (Epitalon class) =E2=80=94 supports the master hormonal= axis. Dosing note: research models support AM dosing rather than PM, even = though it influences melatonin. PM dosing can keep the RS wired at night Vascular/blood vessel bioregulator =E2=80=94 supports the coagulation piece Standard cycling in older literature: 1 cap twice daily for 1=E2=80=932 mon= ths, then 10 days per month thereafter. Important context: that 10-day cycl= e came from anti-aging research where cost and pill burden were the main co= nstraints (24+ separate organ bioregulators stacking up). For research subj= ects with active illness, longer continuous use during the active recovery = phase usually makes more sense. Cycle down once the system stabilizes. Layer 2 =E2=80=94 Repair the Barriers Before pushing the immune system harder, you need the walls intact. Otherwi= se everything you do leaks. Larazotide =E2=80=94 repairs tight junctions (the seals between gut cells).= Sourced through compounding pharmacies for research only, since it=E2=80= =99s a pharmaceutical compound Rebamipide (Lexinox) =E2=80=94 a mast cell stabilizer that=E2=80=99s also a= pproved in Japan for sinus inflammation. Has a side benefit of regulating b= lood sugar in research models. Compounding pharmacy sourcing Peptide-S (the body protection compound class) =E2=80=94 the workhorse for = gut and systemic barrier repair. The properly capped oral form survives dig= estion; injectable also works well KPV =E2=80=94 an anti-inflammatory mast cell stabilizer that=E2=80=99s also= antimicrobial against staph and candida in research. Important sequencing = note: in RS with heavy candida or staph colonization, KPV can produce die-o= ff symptoms because it=E2=80=99s actually killing those organisms. That=E2= =80=99s why it=E2=80=99s often staged later, not first Layer 3 =E2=80=94 Rebuild the Immune System Now that the barriers hold, you can push TH1 up and pull TH2 down without t= he system rebelling. Thymogen Alpha-1 / Thymosin Alpha-1 class =E2=80=94 the cornerstone for rai= sing TH1. Used internationally in research for respiratory infections, immu= ne deficiency, and as a cancer adjunct TB-4 fragment (the N-terminal immune fragment) =E2=80=94 this is a critical= distinction. The full TB-4 molecule has a middle section that stimulates m= ast cells, which is the opposite of what you want in MCAS-presenting RS. Mo= st =E2=80=9CTB-500=E2=80=9D products on the market are actually that middle= (actin-binding) fragment =E2=80=94 useful for tissue regeneration, not for= immune work. Make sure you know which fragment you=E2=80=99re researching Thymalin/Vilon bioregulator combinations =E2=80=94 oral bioregulator route = to similar TH1 support Layer 4 =E2=80=94 Clear the Burned-Out Cells (If Needed) Some research subjects have so many senescent cells (zombie cells =E2=80=94= cells that should have died but didn=E2=80=99t, and are now leaking inflam= mation) that mitochondrial peptides backfire on them. The mitochondria are = too damaged to respond. If that=E2=80=99s the case, run a senolytic protocol first to clear the zom= bie cells: FOXO4-DRI peptide =E2=80=94 research compound for clearing senescent cells Dasatinib + Fisetin combination =E2=80=94 small-molecule alternative used i= n research, typically 3 days per month Start very low. If you have a lot of senescent cells to clear, going in hot= causes a significant reaction. Layer 5 =E2=80=94 Restore Mitochondrial Function With the burned-out cells out of the way, you can rebuild cellular energy. SS-31 (Elamipretide class) =E2=80=94 heals the inner membrane of the mitoch= ondria (the cristae) rather than just stimulating. Good for already-stresse= d mitochondria MOTS-c =E2=80=94 a mitochondrial peptide that=E2=80=99s more stimulating. I= mportant sequencing point: don=E2=80=99t run this early in CIRS RS because = it pushes already-inflamed mitochondria to do more, which produces more rea= ctive oxygen species and more inflammation. It=E2=80=99s a Layer 5 tool, no= t a Layer 1 tool Humanin =E2=80=94 got its name because it made Alzheimer=E2=80=99s research= subjects functional again. Strong neuroprotective profile in research lite= rature Layer 6 =E2=80=94 Now Detox Actually Works This is where binders, sauna, glutathione support, and all the standard det= ox protocols suddenly start producing results in weeks instead of years. Th= e immune system can recognize what to clear, the mitochondria have the ener= gy to push toxins out of cells, and the barriers hold so you don=E2=80=99t = re-absorb what you just excreted. This is also where addressing chronic infections fits =E2=80=94 Lyme, co-in= fections, chronic candida, persistent viral reservoirs. LL-37 belongs here,= which gets its own section below because it=E2=80=99s frequently misused. Layer 7 =E2=80=94 Brain and Nervous System Recovery A lot of CIRS RS have significant neuroinflammation =E2=80=94 brain fog, an= xiety, sleep disruption, autonomic dysregulation. Selank =E2=80=94 calming, immune modulating, useful for anxiety presentatio= ns Semax =E2=80=94 more activating, cognitive support Cerebral peptide blends =E2=80=94 research dosing often needs around 4 caps= per day for full effect (lower doses tend to underperform) Cognitive peptide (Pinealon class) =E2=80=94 works subcortically, ~100mcg r= oughly comparable to ~200mg of cerebral peptide blends in research GHK-Cu =E2=80=94 useful for connective tissue, neuropathy, and anxiety. Sub= cutaneous injection can be irritating; some research protocols dilute it an= d inject intramuscularly to reduce skin reactivity Sequencing note for nasal sprays: a lot of CIRS RS have fungal or bacterial= colonization in the sinuses that doesn=E2=80=99t belong there. Spraying Se= lank or Semax into a colonized sinus underperforms =E2=80=94 clear the terr= ain first, then nasal delivery works as intended. Until then, injectable pe= rforms more reliably. Section 6: VIP =E2=80=94 Why It Gets A Special Warning VIP (Vasoactive Intestinal Peptide) is positioned in the classical mold pro= tocol as the =E2=80=9Cfinal step=E2=80=9D =E2=80=94 the peak of the pyramid= you climb toward once everything else is corrected. Research subjects ofte= n report feeling better on it initially. That=E2=80=99s exactly what makes = it tricky. Looking at the actual mechanism: VIP raises TH2 and lowers TH1. That=E2=80= =99s the opposite of what CIRS RS need. It does suppress both arms somewhat= , but the net shift goes the wrong direction for sustained recovery. What this looks like in practice: RS feel better on VIP, but the moment the= y get re-exposed to mold, perfume, or any inflammatory trigger, they crash = hard. The immune system never actually got rebuilt =E2=80=94 it got pharmac= ologically suppressed into a temporary equilibrium. The crash threshold sta= ys low. There=E2=80=99s also the sinus colonization issue layered on top. VIP nasal= sprayed into a colonized sinus isn=E2=80=99t reaching what it=E2=80=99s su= pposed to reach, and may actually be feeding the wrong response. The research-informed alternative is what=E2=80=99s outlined in the layered= framework above =E2=80=94 rebuild TH1, modulate barriers, fix mitochondria= , clear infections, detox. The =E2=80=9Cfeeling better=E2=80=9D comes from = actual recovery rather than pharmacological masking, and re-exposure resili= ence improves. If VIP gets used in a research context, it=E2=80=99s short-term, late-stage= , after the upstream work is already done =E2=80=94 never as the primary in= tervention. Section 7: LL-37 =E2=80=94 Why It Gets Its Own Section Too LL-37 is the human cathelicidin =E2=80=94 an antimicrobial peptide your imm= une cells naturally produce. It=E2=80=99s effectively the body=E2=80=99s br= oad-spectrum endogenous antibiotic, with research activity against: Gram-positive and gram-negative bacteria Fungi, including Candida species Some enveloped viruses Biofilms =E2=80=94 and this is the critical one for CIRS A quick definition: a biofilm is a slimy protective matrix that microbes bu= ild around themselves. Lyme, co-infections, chronic staph, candida =E2=80= =94 they all hide inside biofilms, and conventional antimicrobials can=E2= =80=99t penetrate the matrix. The infection persists even after years of tr= eatment because the drugs literally can=E2=80=99t reach the bugs. LL-37 in research has shown the ability to disrupt those biofilm matrices, = exposing the organisms to clearance. That=E2=80=99s huge. It=E2=80=99s also= what makes LL-37 dangerous to use early. The catch =E2=80=94 and this matters for CIRS research subjects: LL-37 is not a Layer 1 peptide. Running it early in an RS who has high infl= ammation, MCAS, broken barriers, and dysfunctional mitochondria can produce= severe Herxheimer-style reactions because: Rapid microbial die-off releases endotoxins into a system that can=E2=80=99= t process them The TH2-skewed immune system interprets the die-off as more insult, ramping= inflammation higher Biofilm disruption releases sequestered metals and toxins (biofilms hoard h= eavy metals as part of their defense), and the mitochondria can=E2=80=99t y= et clear them The sequencing rule: LL-37 belongs after immune modulation, after barrier r= epair, and with mitochondrial support already running. It=E2=80=99s an offe= nsive weapon. You don=E2=80=99t deploy offense before the defense is built. Research dosing in the literature varies considerably. The principle that h= olds across the published work: start at a fraction of the target dose and = titrate up. If an RS reacts to half a Peptide-S capsule, they=E2=80=99re go= ing to react to LL-37 =E2=80=94 period. Some research protocols start at 10= % of the eventual target dose and ramp slowly over weeks. LL-37 also has a specific role in research models for chronic sinus coloniz= ation, often paired with biofilm-disrupting compounds. This ties back to th= e nasal spray point earlier =E2=80=94 clearing sinus terrain is often what = unlocks the rest of the protocol working properly. Section 8: The Practical Takeaways CIRS isn=E2=80=99t one thing. It=E2=80=99s an immune dysfunction that lets = multiple problems compound on each other =E2=80=94 mold, infections, metals= , barrier damage, mitochondrial collapse, autonomic dysregulation. Anyone s= elling a single peptide as the answer is missing the picture. The summary of the research-informed sequencing: Get out of the exposure first (no peptide undoes ongoing exposure =E2=80=94= this is non-negotiable) Start with bioregulators to gently modulate the immune system Repair barriers before pushing harder Rebuild TH1 and rebalance TH2 Clear senescent cells if mitochondrial response is sluggish Restore mitochondrial energy production Now detox effectively Address chronic infections =E2=80=94 this is where LL-37 fits, not earlier Rebuild brain and nervous system Transition to long-term maintenance with cycled bioregulators Section 9: A Few Final Notes On cycling. The =E2=80=9C10 days on, then break=E2=80=9D model from older r= esearch came from anti-aging populations where cost and pill burden were th= e main constraints. For research subjects with active multi-system dysfunct= ion, the literature and clinical observation both support longer continuous= use during the active recovery phase, transitioning to cycling once the sy= stem has stabilized. There=E2=80=99s no single right protocol =E2=80=94 it = depends entirely on where the RS is in the recovery arc. On sourcing. Oral bioregulator quality varies wildly. The capping (acetylat= ion and amidation) determines whether the molecule survives stomach acid. U= ncapped or salt-form versions look identical on a label but perform very di= fferently. For research-only pharmaceutical compounds like Larazotide and R= ebamipide, compounding pharmacy sourcing is the standard route. On expectations. This framework typically cuts recovery time significantly = compared to binder-only approaches =E2=80=94 the kind of timeline where wha= t used to take 5 years takes 1 to 2, and milder cases sometimes resolve in = months. But CIRS is genuinely complex, and individual response varies. Work= ing with a clinician who understands this terrain is the difference between= a structured recovery and another decade of trial and error. Drop questions below =E2=80=94 happy to go deeper on any specific layer, bi= omarker, peptide class, or sequencing question. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOVGd4TlRFNE1Dd2lhV0YwSWpveE56YzNOR= El3TXpZd0xDSmxlSEFpT2pFNE1EZzVOVFl6TmpBc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LlN4cVFNZ1V6VG1mNmk4ZVgtLWNfcUN2S0R= QNWpydWoxOWFZMkV5YTBTelEiLCJwIjoxOTU4MTUxODAsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc3NDIwMzYwLCJleHAiOjIwOTI5OTYzNjAsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.iry_yHH1R_zN-SVP1OX4IuInbiExs8rKsg9ZL8f= BmRY? --f293934ab6237258b5faca002d67a2252defc5c892e0a591f07df086a11b Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = Mold Toxicity & Peptides: A Comprehensive Walkthrough=3D""
Read this first: Everything below is for resea= rch and educational purposes only.
͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­
=
<= /td>
Forwarded this email? Subscribe here for more=

Mold Toxicity & Peptides: A Comprehensive Walkthrough

<= table class=3D"post-meta" role=3D"presentation" width=3D"100%" border=3D"0"= cellspacing=3D"0" cellpadding=3D"0" style=3D"margin: 1em 0;height: 20px;al= ign-items: center;">
<= tr>
Derek
 
=3D""

Read this first:= Everything below is for research and educational purposes only. Noth= ing here is medical advice. All peptide references are framed for research = subjects (RS), not for human consumption. If you think you’re dealing= with mold illness, work with a qualified clinician who knows this terrain.=

Section 1: What Mold Toxicity Actually Is

You’ll hear this called several names — mold illn= ess, biotoxin illness, or its clinical name CIRS (Chronic In= flammatory Response Syndrome). They all describe the same th= ing: a multi-system illness that develops when someone with a susceptible i= mmune system gets exposed to water-damaged buildings and the toxins they ha= rbor.

= 3D""
3D""
<= tbody>
READ IN APP3D""
 
3D"image.png"

Those toxin= s include:

  • Mycotoxins — pois= onous compounds produced by mold itself

  • Endotoxins — fra= gments of bacterial cell walls (water damage breeds bacteria too, not just = mold)

  • Beta-glucans — pieces of fungal cell walls that tr= igger immune responses

  • Inflammagens — a catch-all term f= or anything in the environment that drives inflammation

    • Here’s the part most people miss: = healthy immune systems generally clear all of this. The peop= le who end up stuck in CIRS almost always had something else going on first= — chronic infections (Lyme, Epstein-Barr, co-infections), a heavy me= tal burden, prior viral hits, or significant unrelenting stress. Mold is us= ually the straw that breaks the camel’s back, not the only problem in= the barn.

    This is why one family member can be comp= letely wrecked while everyone else in the same house feels fine. Same expos= ure, different immune terrain.

    Section 2: How Mold Wrecks T= he Immune System

    This section gets a bit technical, but it= matters because the peptide protocol makes a lot more sense once you under= stand what’s actually broken.

    The TH1/TH2 imb= alance. Your immune system has two main “arms”:<= /span>

    • TH1 is your killer side = 212; natural killer cells, cytotoxic T-cells, the parts that hunt down and = destroy infections, abnormal cells, and cancers

    • TH2 is your an= tibody/inflammatory side — useful in normal amounts, but when it domi= nates you get allergies, autoimmunity, and mast cell problems

    In CIRS, TH1 gets suppressed and TH2 goes up. So your a= bility to fight infections drops while your ability to inflame and react to= everything goes through the roof. Worst of both worlds.

    T-cell exhaustion. Imagine an employee who’s bee= n overworked for years. They still show up, but they’ve checked out. = That’s what happens to immune cells under chronic insult. They’= re physically present in lab tests but functionally useless. Same thing hap= pens in cancer.

    Mitochondrial dysfunction. Mitochondria are the energy producers inside your cells. When= they break down, the cell can’t generate enough ATP (cellular energy= ) to do basic things — including pushing toxins out. This is why peop= le on binders for years still don’t detox. The garbage trucks are run= ning, but the houses can’t carry the trash to the curb.

    Immune activation of coagulation. When the= body senses chronic infection or inflammation, it lays down fibrin (a stic= ky protein web) trying to wall off invaders. The problem: that fibrin coats= your cells and slows everything down. Oxygen that normally takes about 2 s= econds to enter a cell can take up to 2 minutes. That’s where the = 220;air hunger” feeling comes from — your lungs are fine, but y= our cells are starving.

    Pineal/HPA axis dysf= unction. The pineal gland and hypothalamus-pituitary axis ru= n the body’s master hormonal commands. When they get dysregulated, yo= u see the classic CIRS pattern — suppressed TSH, low T3, “tired= but wired,” disrupted sleep, and standard thyroid panels that look &= #8220;normal” while the person feels like they’re dying.=

    Barrier collapse. The gut lining an= d the blood-brain barrier are supposed to be selective walls. In CIRS they = get leaky, which is part of why MCAS (mast cell activation syndrome —= basically an immune system that reacts to everything) so often shows up al= ongside mold illness.

    The biomarkers clinician= s track for this: C4a, TGF-β1, MSH, VIP, MMP-9, and nat= ural killer cell activity. A note on testing — Quest t= ends to mishandle the NK activity test. LabCorp is more reliable for that o= ne specifically.

    Section 3: The Two Approaches ̵= 2; Downstream vs. Upstream

    The classical approach to= mold treatment uses binders (compounds like = cholestyramine that grab toxins in the gut and carry them out). This works,= but it’s downstream — you’re catching toxins after they&= #8217;re already loose, hoping to clear them faster than they’re bein= g released. It can take 5 to 8 years on this approach, and a lot of people = stall out.

    The newer framework looks upstream — fix the immune system and mitochondri= a first, then detox. The logic:

    • If your immune sys= tem is broken, it can’t recognize or clear what’s colonizing yo= u

    • If your mitocho= ndria can’t make energy, your cells physically can’t push toxin= s out

    • If your bar= riers are leaky, you’re re-absorbing what you just excreted

      • <= /ul>

      Fix the upstream problems and the downstream cleanup goes = from years to months. Binders still have a role — they just work way = better when the system is primed to actually use them.

      Sect= ion 4: Why Peptides Fit Here

      Peptides are short chains of = amino acids (the building blocks of proteins). They’re naturally occu= rring signaling molecules — your body makes thousands of them. They t= ell cells what to do.

      There are two main categories worth k= nowing for this conversation:

      Peptides (general category) — usually 5 to 50 amino acids long. They sit on= cell surface receptors and trigger a cascade of effects inside the cell. T= hink of them as keys that fit specific locks.

      Bioregulators — a smaller subcategory, only 2 to 4 a= mino acids long. Because they’re so small, they slip into the cell, i= nto the nucleus, and bind directly to genes. They work epige= netically, meaning they influence which genes get turned on = or off without changing the DNA itself. Bioregulators are gentle, slow-onse= t, and rarely cause reactions — which makes them ideal for sensitive = research subjects.

      The reason peptides work so well = together: unlike pharmaceuticals, where stacking drugs multiplies side effe= cts, peptides tend to complement each other. You can layer a bioregulator w= ith two or three peptides and get a synergistic effect rather than a toxici= ty problem.

      A note on oral peptides: when a peptide i= s capped (chemists add an acetyl group to one= end and an amide group to the other), it survives stomach acid and absorbs= well. Uncapped peptides get destroyed before they can work. The “arg= inine salt” version of certain peptides looks similar on a label but = doesn’t survive — it’s marketed as “stable” b= ut functionally less effective.

      Section 5: The Layer= ed Research Framework

      This is the sequencing that’s = emerging from clinical observation. Each layer prepares the system for the = next. Skipping ahead causes problems — running offensive peptides bef= ore defensive ones is a common mistake that produces severe reactions.

      <= h3 class=3D"header-anchor-post" style=3D"position: relative;font-family: 'S= F Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkMacSyste= mFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Seg= oe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing: an= tialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: optimize= legibility;-moz-appearance: optimizelegibility;appearance: optimizelegibili= ty;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-si= ze: 1.375em;">Layer 1 — Calm and Modulate

      For sensit= ive research subjects (which most CIRS-affected RS are), bioregulators come= first. They’re the gentlest entry point and rarely produce reactions= =2E

      • Thymus bioregulator — modu= lates the immune system as a whole, the foundation peptide

        • <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

        Pineal bioregulato= r (Epitalon class) — supports the master hormonal axis= =2E Dosing note: research models suppor= t AM dosing rather than PM, even thoug= h it influences melatonin. PM dosing can keep the RS wired at night<= /p>

      • Vascular/= blood vessel bioregulator — supports the coagulation p= iece

      Standard cycling in older literature:= 1 cap twice daily for 1–2 months, then 10 days per month thereafter.= Important context: that 10-day cycle came from anti-aging research where c= ost and pill burden were the main constraints (24+ separate organ bioregula= tors stacking up). For research subjects with active illness, longer contin= uous use during the active recovery phase usually makes more sense. Cycle d= own once the system stabilizes.

      Layer 2 — Repair = the Barriers

      Before pushing the immune system harder, you = need the walls intact. Otherwise everything you do leaks.

      • Larazotide — repairs tight junctions (the sea= ls between gut cells). Sourced through compounding pharmacies for research = only, since it’s a pharmaceutical compound

      • Rebamipide (Lexinox) — a mast cell stabilizer that’s also approved in Japa= n for sinus inflammation. Has a side benefit of regulating blood sugar in r= esearch models. Compounding pharmacy sourcing

      • Peptide-S (the body protection = compound class) — the workhorse for gut and systemic b= arrier repair. The properly capped oral form survives digestion; injectable= also works well

      • KPV — an anti-inflammatory mast cell st= abilizer that’s also antimicrobial against staph and candida in resea= rch. Important sequencing note: in RS with heavy candida or staph colonizat= ion, KPV can produce die-off symptoms because it’s actually killing t= hose organisms. That’s why it’s often staged later, not first

      Layer 3 — Rebuild the Immune System=

      Now that the barriers hold, you can push TH1 up and pull = TH2 down without the system rebelling.

      • Thymogen A= lpha-1 / Thymosin Alpha-1 class — the cornerstone for = raising TH1. Used internationally in research for respiratory infections, i= mmune deficiency, and as a cancer adjunct

      • TB-4 fragment (the N-terminal immun= e fragment) — this is a critical distinction. The full= TB-4 molecule has a middle section that stimulates mast cells, which is th= e opposite of what you want in MCAS-presenting RS. Most “TB-500”= ; products on the market are actually that middle (actin-binding) fragment = — useful for tissue regeneration, not for immune work. Make sure you = know which fragment you’re researching

      • Thymalin/Vilon bioregulator comb= inations — oral bioregulator route to similar TH1 supp= ort

      Layer 4 — Clear the Burned-Out= Cells (If Needed)

      Some research subjects have so ma= ny senescent cells (zombie cells — cell= s that should have died but didn’t, and are now leaking inflammation)= that mitochondrial peptides backfire on them. The mitochondria are too dam= aged to respond.

      If that’s the case, run= a senolytic protocol first to clear the zomb= ie cells:

      • FOXO4-DRI peptide= — research compound for clearing senescent cells

      • Dasatinib + Fisetin c= ombination — small-molecule alternative used in resear= ch, typically 3 days per month

      Start very = low. If you have a lot of senescent cells to clear, going in hot causes a s= ignificant reaction.

      Layer 5 — Restore Mitochondria= l Function

      With the burned-out cells out of the way, you c= an rebuild cellular energy.

      • SS-31 (Elamipretide c= lass) — heals the inner membrane of the mitochondria (= the cristae) rather than just stimulating. Good for already-stressed mitoch= ondria

      • MOTS-c — a mitochondrial peptide that’s mor= e stimulating. Important sequencing point: don’t run this early in CI= RS RS because it pushes already-inflamed mitochondria to do more, which pro= duces more reactive oxygen species and more inflammation. It’s a Laye= r 5 tool, not a Layer 1 tool

      • Humanin — got its name beca= use it made Alzheimer’s research subjects functional again. Strong ne= uroprotective profile in research literature

      Layer 6 — Now Detox Actually Works

      This is whe= re binders, sauna, glutathione support, and all the standard detox protocol= s suddenly start producing results in weeks instead of years. The immune sy= stem can recognize what to clear, the mitochondria have the energy to push = toxins out of cells, and the barriers hold so you don’t re-absorb wha= t you just excreted.

      This is also where addressing ch= ronic infections fits — Lyme, co-infections, chronic candida, persist= ent viral reservoirs. LL-37 belongs here, whi= ch gets its own section below because it’s frequently misused.=

      Layer 7 — Brain and Nervous System Recovery

      A lot of CIRS RS have significant neuroinflammation — brai= n fog, anxiety, sleep disruption, autonomic dysregulation.

      • Semax — more activating, cogni= tive support

      • Cerebral peptide blends — research dosing o= ften needs around 4 caps per day for full effect (lower doses tend to under= perform)

      • <= strong>Cognitive peptide (Pinealon class) — works subc= ortically, ~100mcg roughly comparable to ~200mg of cerebral peptide blends = in research

      • Sequencing note for nasal sprays: a lot of = CIRS RS have fungal or bacterial colonization in the sinuses that doesnR= 17;t belong there. Spraying Selank or Semax into a colonized sinus underper= forms — clear the terrain first, then nasal delivery works as intende= d. Until then, injectable performs more reliably.

        Section 6= : VIP — Why It Gets A Special Warning

        VIP (V= asoactive Intestinal Peptide) is positioned in the classical= mold protocol as the “final step” — the peak of the pyra= mid you climb toward once everything else is corrected. Research subjects o= ften report feeling better on it initially. That’s exactly what makes= it tricky.

        Looking at the actual mechanism: <= /span>VIP raises TH2 and lowers TH1. That’s th= e opposite of what CIRS RS need. It does suppress both arms somewhat, but t= he net shift goes the wrong direction for sustained recovery.

        What this looks like in practice: RS feel better on VIP, but the = moment they get re-exposed to mold, perfume, or any inflammatory trigger, t= hey crash hard. The immune system never actually got rebuilt — it got= pharmacologically suppressed into a temporary equilibrium. The crash thres= hold stays low.

        There’s also the sinus colonization i= ssue layered on top. VIP nasal sprayed into a colonized sinus isn’t r= eaching what it’s supposed to reach, and may actually be feeding the = wrong response.

        The research-informed alternative is what&#= 8217;s outlined in the layered framework above — rebuild TH1, modulat= e barriers, fix mitochondria, clear infections, detox. The “feeling b= etter” comes from actual recovery rather than pharmacological masking= , and re-exposure resilience improves.

        If VIP gets used in = a research context, it’s short-term, late-stage, after the upstream w= ork is already done — never as the primary intervention.

        Section 7: LL-37 — Why It Gets Its Own Section Too

        LL-37 is the human cathelicidin — an anti= microbial peptide your immune cells naturally produce. It’s effective= ly the body’s broad-spectrum endogenous antibiotic, with research act= ivity against:

        • Gram-positive and gram-negative ba= cteria

        • Fungi, inc= luding Candida species

        • Some enveloped viruses

        • Biofilms — and this is the critica= l one for CIRS

        A quick definition: a= biofilm is a slimy protective matrix that mi= crobes build around themselves. Lyme, co-infections, chronic staph, candida= — they all hide inside biofilms, and conventional antimicrobials can= ’t penetrate the matrix. The infection persists even after years of t= reatment because the drugs literally can’t reach the bugs.

        =

        LL-37 in research has shown the ability to disrupt those biofi= lm matrices, exposing the organisms to clearance. That’s huge. ItR= 17;s also what makes LL-37 dangerous to use early.

        = The catch — and this matters for CIRS research subjects:

        =

        LL-37 is not a Layer 1 pep= tide. Running it early in an RS who has high inflammation, MCAS, broken bar= riers, and dysfunctional mitochondria can produce severe Herxheimer-style r= eactions because:

        1. Rapid microbial die-off releases end= otoxins into a system that can’t process them

        2. The TH2-skewed immune system interpre= ts the die-off as more insult, ramping inflammation higher

          3. <= li style=3D"margin: 8px 0 0 32px;">

          Biofilm disruption releases se= questered metals and toxins (biofilms hoard heavy metals as part of their d= efense), and the mitochondria can’t yet clear them

          The sequencing rule: LL-37 belongs afte= r immune modulation, after bar= rier repair, and with mitochondrial support a= lready running. It’s an offensive weapon. You don’t deploy offe= nse before the defense is built.

          Research dosi= ng in the literature varies considerably. The principle that holds across t= he published work: start at a fraction of the target dose an= d titrate up. If an RS reacts to half a Peptide-S capsule, t= hey’re going to react to LL-37 — period. Some research protocol= s start at 10% of the eventual target dose and ramp slowly over weeks.

          LL-37 also has a specific role in research models for ch= ronic sinus colonization, often paired with biofilm-disrupting compounds. T= his ties back to the nasal spray point earlier — clearing sinus terra= in is often what unlocks the rest of the protocol working properly.

          Section 8: The Practical Ta= keaways

          CIRS isn’= ;t one thing. It’s an immune dysfunction that lets multiple problems = compound on each other — mold, infections, metals, barrier damage, mi= tochondrial collapse, autonomic dysregulation. Anyone selling a single pept= ide as the answer is missing the picture.

          The summary of th= e research-informed sequencing:

            =

          1. Get out of the exposure first (no peptide undoes ong= oing exposure — this is non-negotiable)

          2. Repair barriers before pushing harder

          3. Rebuild TH1 and rebalance TH2

          4. = Clear senescent cells if mitochondrial response is sluggish

          5. Restore mitochondrial energy production

          6. Now detox effectively

          7. Address = chronic infections — this is where LL-37 fits, not earlier

            8. Rebuild brain and nervous system

          8. Transition to long-term maintenance with cycled bioregulators

            =
          Section 9: A Few Final Notes

          On cycling. The “10 days on, then break” model= from older research came from anti-aging populations where cost and pill b= urden were the main constraints. For research subjects with active multi-sy= stem dysfunction, the literature and clinical observation both support long= er continuous use during the active recovery phase, transitioning to cyclin= g once the system has stabilized. There’s no single right protocol &#= 8212; it depends entirely on where the RS is in the recovery arc.

          On sourcing. Oral bioregulator quality= varies wildly. The capping (acetylation and amidation) determines whether = the molecule survives stomach acid. Uncapped or salt-form versions look ide= ntical on a label but perform very differently. For research-only pharmaceu= tical compounds like Larazotide and Rebamipide, compounding pharmacy sourci= ng is the standard route.

          On expectations. This framework typically cuts recovery time significantly com= pared to binder-only approaches — the kind of timeline where what use= d to take 5 years takes 1 to 2, and milder cases sometimes resolve in month= s. But CIRS is genuinely complex, and individual response varies. Working w= ith a clinician who understands this terrain is the difference between a st= ructured recovery and another decade of trial and error.

          Drop questions below — happy to go deeper on any specific layer,= biomarker, peptide class, or sequencing question.

          Upgrade to paid

          You're currently a free subscriber t= o Research Radar. For the = full experience, upgrade your subscription.=

          Upgrade to paid

           
          =
          <= /table>
          3D""Share
           
           
          =
          = Like
          3D""Comment=
          3D""
           

          © = 2026 Derek Pruski
          548 Market Street PMB 72296, San Francisc= o, CA 94104
          Unsubscribe<= /span>

          3D"Start

          3D""= 3D"" --f293934ab6237258b5faca002d67a2252defc5c892e0a591f07df086a11b--